Compare AbCellera Biologics Inc (ABCL) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Nomura Holdings Inc — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Nomura Holdings Inc trades at $9.41 (market cap $27.73B). The key difference: Nomura Holdings Inc is far larger — about 11.8× AbCellera Biologics Inc's market cap, and Nomura Holdings Inc pays a 3.44% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | NMR | |
|---|---|---|
Market Cap | $2.35B | $27.73B |
Sector | Health | Financials |
52-Week High | $8.12 | $9.54 |
52-Week Low | $2.78 | $6.30 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Nomura Holdings (NMR) trades at $9.42, up 3.97% with a bullish technical signal. The stock shows strong fundamentals with record annual profit of $340.74B (20.49% margin) and revenue growth to $1.66T. Recent news highlights CEO pay increase following record performance and US expansion plans. Technical indicators show bullish momentum with RSI at neutral levels, while analyst consensus leans hold-heavy with 66.7% neutral rating.
Outlook remains positive with expanding profitability and strategic acquisitions, though recent earnings misses and rising debt-to-asset ratio (26.25%) present execution risks. The stock trades at attractive valuations (P/E 12.66, P/B 1.19) but faces integration challenges from Macquarie acquisition and geopolitical uncertainties affecting growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
